1300019-48-0

Basic information

• Product Name: methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate
• Synonyms: methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate
• CAS NO: 1300019-48-0
• Molecular Weight: 613.066
• Mol File: 1300019-48-0.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate(1300019-48-0)
• EPA Substance Registry System: methyl N¹-[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]-N²-{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}-L-α-asparaginate(1300019-48-0)

Safety Data

• Hazardous Substances Data: 1300019-48-0(Hazardous Substances Data)

Upstream product

• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 38527-50-3 2-methyl-6-(methoxy)-3,1-benzoxazin-4-one 
• 596095-91-9 methyl (3S)-4-chloro-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-oxobutanoate 
• 91713-54-1 [2-amino-5-(methyloxy)phenyl](4-chlorophenyl)methanone 
• 145038-53-5 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methoxy-4-oxobutanoic acid 

Downstream Products

• 1300019-46-8 (S)-methyl 2-(5-(4-chlorophenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetate 
• 1300019-43-5 (S)-methyl 2-(5-(4-chlorophenyl)-7-methoxy-2-thioxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetate 
• 1300019-41-3 methyl 2-[(3S,2Z)-2-(acetylhydrazono)-5-(4-chlorophenyl)-7-(methyloxy)-1,3-dihydro-1,4-benzodiazepin-3-yl]acetate 
• 1300019-40-2 methyl 2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzol[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetate 
• 1300019-38-8 [(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetic acid 
• 1300019-50-4 1,1-dimethylethyl [5-({[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetyl}amino)pentyl]carbamate 
• 1300019-52-6 N-(5-aminopentyl)-2-[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]acetamide trifluoroacetate 
• 1426686-73-8 (S)-tert-butyl (2-(2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetamido)ethyl)carbamate 
• 1426687-02-6 (S)-tert-butyl (2-((6-(4-chlorophenyl)-4-(2-(ethylamino)-2-oxoethyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-8-yl)oxy)ethyl)carbamate 
• 1426686-92-1 (S)-2-(8-(2-aminoethoxy)-6-(4-chlorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-N-ethylacetamide 
• 1426687-04-8 tert-butyl (2-(2-(((4S)-6-(4-chlorophenyl)-4-(2-(ethylamino)-2-oxoethyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-8-yl)oxy)ethoxy)ethyl)carbamate 
• 1426687-08-2 tert-butyl (17-(((4S)-6-(4-chlorophenyl)-4-(2-(ethylamino)-2-oxoethyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-8-yl)oxy)-3,6,9,12,15-pentaoxaheptadecyl)carbamate 
• 1352937-77-9 (S)-6-(4-chlorophenyl)-4-(2-(ethylamino)-2-oxoethyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-8-yl trifluoromethanesulfonate 

Relevant articles and documents

Preparation of Methyltriazolo[1,4]benzodiazepine via Oxidative Activation of a Thiolactam for the Synthesis of BET Inhibitor Molibresib

A novel oxidative activation of a thiolactam was developed for the preparation of methyltriazolo[1,4]benzodiazepine in a single step. A sulfenic acid (R-SOH) was proposed as the activated intermediate with the concurrent formation of acetylhydrazone from acethydrazide and cyclocondensation to the triazole. A version of the method with 35% peracetic acid was scaled up to 40 kg as a part of the new route for the synthesis of BET inhibitor molibresib (GSK525762). The thiolactam was prepared from commercially available (2-amino-5-methoxyphenyl)(4-chlorophenyl)methanone in two steps in 66% yield. The concise four-step synthesis delivered 52 kg of molibresib of >99.9% ee in an overall 41% yield from the ketone. The condition for the methyltriazole was mild and free of racemization of the sensitive stereocenter. The oxidative method, with several advantages to the known methods, should be applicable to the synthesis of alkyltriazoles from other thiolactams and acylhydrazines.

THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM

The present application is directed to a therapeutically useful compound, comprised of two monomers that are linked to each other through two or more reversible covalent bonds. Each monomer is a polyfunctionalized molecule comprising a bioorthogonal linker element and ligand or pharmacophore, wherein the linker and ligand/pharmacophore are covalently coupled to each other either directly or through an optional connector moiety.

BET protein inhibitor and applications thereof

The present invention relates to a compound represented by a general formula (I) and used for inhibiting BET proteins, particularly BRD4, and uses of the compound in hyperproliferative diseases, mainly in prevention or treatment of tumor diseases, hyperplasia of prostate, inflammatory diseases, autoimmune diseases, sepsis, viral infections, vascular diseases and neurological diseases. The formula(I) is defined in the specification.